BCG-unresponsive non-muscle invasive bladder cancer: recommendations from the IBCG
Por:
Kamat, AM, Colombel, M, Sundi, D, Lamm, D, Boehle, A, Brausi, M, Buckley, R, Persad, R, Palou, J, Soloway, M, Witjes, JA
Publicada:
1 abr 2017
Resumen:
Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer. This Review of treatment options after BCG failure focuses on principles of optimal management emerging therapies, thus enabling a synthesis of recommendations for management for such patients.
Filiaciones:
Kamat, AM:
MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd,Unit 1373, Houston, TX 77054 USA
Colombel, M:
Univ Claude Bernard, Hop Edouard Herriot, Dept Urol, Urol Pavillon 5,5 Pl Arsonval, F-69003 Lyon, France
Sundi, D:
MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd,Unit 1373, Houston, TX 77054 USA
Lamm, D:
Univ Arizona, Dept Surg, 3815 East Bell Rd,Suite 1210, Phoenix, AZ 85032 USA
BCG Oncol, 3815 East Bell Rd,Suite 1210, Phoenix, AZ 85032 USA
Boehle, A:
HELIOS Agnes Karll Hosp, Dept Urol, Hochkamp 21, D-23611 Bad Schwartau, Germany
Brausi, M:
B Ramazzini Hosp, AUSL Modena, Dept Urol, Via G Molinari 1, I-41012 Carpi Modena, Italy
Buckley, R:
North York Gen Hosp, Dept Urol, 1333 Sheppard Ave East,Suite 222, N York, ON M2J 1V1, Canada
Persad, R:
Southmead Hosp, Dept Urol Surg, Brunel Bldg,Southmead Rd, Bristol BS10 5NB, Avon, England
Bristol Urol Inst, Brunel Bldg,Southmead Rd, Bristol BS10 5NB, Avon, England
Palou, J:
Univ Autonoma Barcelona, Fundacio Puigvert, Dept Urol, Carrer Cartagena 340-350, Barcelona 08025, Spain
Soloway, M:
Mem Hlth Syst, Mem Canc Inst, Div Urol Oncol, 20801 Biscayne Blvd,Suite 203, Aventura, FL 33180 USA
Witjes, JA:
Radboud Univ Nijmegen, Med Ctr, Dept Urol, POB 9101, NL-6500 HGB Nijmegen, Netherlands
|